Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
FMF50: a score for assessing outcome in familial Mediterranean fever.
[familial mediterranean fever]
Colchicine
is
the
main
treatment
for
familial
Mediterranean
fever
(
FMF
)
.
However
,
biological
agents
and
other
treatments
are
available
for
patients
who
are
unable
to
receive
optimal
treatment
.
To
develop
outcome
criteria
that
define
response
to
treatment
.
Two
rounds
of
Delphi
exercise
were
followed
by
a
consensus
conference
enabling
the
definition
of
the
criteria
to
be
employed
.
Data
for
patients
with
FMF
responding
and
resistant
to
their
treatment
were
obtained
from
the
FMF
Arthritis
Vasculitis
and
Orphan
disease
Research
in
paediatric
rheumatology
(
FAVOR
)
website
.
The
suggested
criteria
were
analysed
and
validated
in
this
patient
cohort
.
Sensitivity
/
specificity
measures
and
the
ability
of
the
score
to
discriminate
between
patients
with
active
and
inactive
disease
via
the
best
cut-off
score
were
calculated
by
a
receiver
operating
characteristic
analysis
.
Compliance
with
the
maximum
dose
of
the
drug
was
considered
essential
for
evaluation
of
the
patients
.
Seven
criteria
were
suggested
in
the
consensus
conference
.
The
performance
of
each
criterion
,
in
differentiating
between
resistant
and
responsive
patients
,
was
tested
.
The
final
set
of
criteria
was
defined
as
at
least
50
%
improvement
in
five
of
six
criteria
,
without
worsening
in
any
one
defined
response
to
treatment
with
a
very
high
sensitivity
and
specificity
.
The
items
of
this
FMF
50
included
:
1
.
Percentage
change
in
the
frequency
of
attacks
with
the
treatment
.
2
.
Percentage
change
in
the
duration
of
attacks
with
the
treatment
.
3
.
Patients
/
parents
'
global
assessment
of
disease
severity
(
10
cm
visual
analogue
scale
(
VAS
)
)
.
4
.
Physicians
'
global
assessment
of
disease
severity
(
10
cm
VAS
)
.
5
.
Percentage
change
in
arthritis
attacks
with
the
treatment
.
6
.
Percentage
change
in
C-
reactive
protein
,
erythrocyte
sedimentation
rate
or
serum
amyloid
A
level
with
the
treatment
.
The
FMF
50
produced
is
a
user-friendly
measurement
tool
to
guide
physicians
and
can
be
used
in
clinical
trials
.
Diseases
Validation
Diseases presenting
"visual analogue scale"
symptom
cutaneous mastocytosis
familial mediterranean fever
pyomyositis
trochlear dysplasia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
